AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02912507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CynoSure PicoSure 755nm laser
Description: high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
Study NCT02140515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutropin alfa
Description: Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
Study NCT02140515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa and Lutropin alfa
Description: Administration of (rFSH) and (rLH)
Study NCT01569594 — intervention group
Intervention type: DEVICE
Intervention: CorMatrix ECM for Carotid Repair
Description: Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
Study NCT02471794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Health Planning Shared Medical Appointment
Description: The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
Study NCT02807207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A
Study NCT02807207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B
Study NCT02807207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C
Study NCT03721341 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Radiation
Description: Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Immunotherapy may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: Hormones may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormones
Description: Hormones may be given as indicated.
Study NCT03721341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Observation only is acceptable if this is the standard practice.
Study NCT03721341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation only is acceptable if this is the standard practice.
Study NCT03721341 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
Study NCT04157777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineum massage with olive oil
Description: Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale.
Study NCT03573843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention software
Description: All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
Study NCT03573843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
Study NCT03910309 — intervention group
Intervention type: DEVICE
Intervention: TLIF with Titan TT/TO interbody cage
Description: fusion surgery
Study NCT02940392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.
Study NCT00616304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine hydrochloride
Description: Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
Study NCT00616304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
Study NCT01030055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258 (dovitinib)
Description: bioavailability (anhydrate capsules) food (monohydrae capsules)
Study NCT04522453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based version of mental health Gap Action Program-Intervention Guide
Description: A paper-based guide for diagnosis and management of mental disorders in primary care.
Study NCT04522453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital version of the mental health Gap Action Program-Intervention Guide
Description: A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
Study NCT02058953 — intervention group
Intervention type: PROCEDURE
Intervention: Craniotomy scheduled
Description: Resection of affected brain tissue
Study NCT02058953 — intervention group
Intervention type: PROCEDURE
Intervention: Collection for non-craniotomy
Description: CSF, Blood, biopsy
Study NCT03326778 — intervention group
Intervention type: PROCEDURE
Intervention: AVR and CABG
Description: Combined AVR with CABG
Study NCT02278926 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound measurements
Study NCT02278926 — intervention group
Intervention type: OTHER
Intervention: Tapping and body inspection to define the area of insulin injection
Description: Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
Study NCT02794766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin+SS
Description: Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Study NCT02794766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S salivarius
Description: Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Study NCT02794766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 gum each 12 hours for 10 days
Study NCT03018899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Ultrasound guided two-segment paravertebral block
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
Study NCT03018899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: thoracic epidural anesthesia
Study NCT01083823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental health telemetry (MHT)
Description: Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
Study NCT02668458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow nasal canula oxygen therapy
Description: Pre-oxygenation with high-flow nasal canula oxygen therapy
Study NCT02668458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Pre-oxygenation with non-invasive ventilation
Study NCT00659074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, single-dose, fasting
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
Study NCT00659074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: ODT, single-dose, fasting
Study NCT03955614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pedal-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.
Study NCT03955614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ML-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
Study NCT03955614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NoGo
Description: The operating theatre environment is recorded to observe baseline teamwork.
Study NCT01337336 — intervention group
Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate
Description: combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
Study NCT01337336 — intervention group
Intervention type: DRUG
Intervention: Anticholinergics
Description: tiotropium; ipratropium alone; or ipratropium + albuterol
Study NCT04619615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous self-directed digital training
Description: Resident participants will be able to complete the digital training at their own pace.
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
Study NCT04619615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronous large group online workshop
Description: Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
Study NCT03530943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Activities
Description: Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
Study NCT03530943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Stress Management tools
Description: Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
Study NCT03530943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Stress Management tools
Description: Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
Study NCT05127707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
Study NCT02246855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex® (Human Normal Immunoglobulin)
Study NCT05206721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open tracheal suction system flushing with chlorhexidine
Description: After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
Study NCT01505959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Usual CPAP treatment
Study NCT01505959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP treatment
Description: CPAP treatment with telemedicine system
Study NCT00811603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin (Timing of Antibiotic Prophylaxis)
Description: Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Study NCT00811603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin (Timing of Antibiotic Prophylaxis)
Description: Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Study NCT04038489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
Study NCT04038489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
Study NCT04038489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
Study NCT02900820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuing antibiotic therapy
Description: Patients assigned to this group will be asked to discontinue antibiotic therapy.
Study NCT02900820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuing antibiotic therapy
Description: Patients assigned to this group will be asked to complete antibiotic therapy.
Study NCT01752205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 45mg/m2/w,total 6 weeks
Study NCT01752205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45mg/m2/w,total 6 weeks
Study NCT01752205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg/d,days 1-42,total 6 weeks
Study NCT01752205 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study NCT01752205 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT01226225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
Study NCT01226225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate endurance training
Description: Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
Study NCT00764361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
Study NCT00764361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: placebo gel applied topically to the wound once daily for 20 weeks
Study NCT00547651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
Study NCT00547651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course